Hematologic Oncology Update Multiple Myeloma — Fourth Annual National General Medical Oncology Summit
May 31, 2025
In this engaging discussion, Dr. Natalie Callender and Dr. Tom Martin, renowned experts in hematologic oncology, tackle the intricacies of multiple myeloma treatment. They delve into unique challenges for elderly patients, highlighting key findings from the AQUILA trial that enhance treatment strategies. The episode also explores the promising role of Selenexer and advances in CAR T-cell therapies, bringing light to the complexities of neurotoxicity and emerging therapies. The conversation emphasizes personalized treatment approaches for better outcomes in diverse patient demographics.
AI Snips
Chapters
Transcript
Episode notes
Transplant Timing and Benefits
- Transplant typically deepens remission and prolongs PFS, especially in patients with high-risk cytogenetics.
- Early transplant within the first year is preferred over delayed transplant for better outcomes.
Belantamab in Frail Patients
- Belantamab is a useful easy-to-use drug for older or frail myeloma patients, especially with attenuated dosing.
- Cellular therapies may be preferred for Dera-Len refractory patients over prolonged quadruplet maintenance.
Selinexor Management Tips
- Use multiple anti-nausea drugs as prophylaxis before starting selinexor therapy.
- Dose reduction improves tolerability and allows longer treatment duration.